BCLI News and Press, Brainstorm Cell Therapeutics Inc.

2024-07-08 12:14:59 ET More on IPOs Eureka Acquisition prices $50M IPO at $10 per share Canadian medtech Breathe BioMedical sets terms for $8M US IPO IPO roundup: SLRA, OS, and more IPO roundup: WEBTOON Entertainment, LandBridge, and more Read the f...

2024-07-08 10:12:09 ET Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program July 8, 2024 8:00 AM ET Company Participants Joyce Lonergan - LifeSci Advisors Chaim Lebovits - President and Chief Executive Officer Haro Hartounian - Exe...

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program PR Newswire A conference call and webcast will be held Monday, July 8 , at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeut...

2024-06-27 09:51:12 ET More on BrainStorm Cell Therapeutics BrainStorm appoints Haro Hartounian as COO BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical ear...

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics fo...

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial PR Newswire NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell thera...

2024-06-20 06:29:52 ET BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings...

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer PR Newswire Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK , June 20, 2024 /PRNewswire/ -- Br...

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation Canada NewsWire FROM ACF EQUITY RESEARCH HEALTHCARE TEAM NASDAQ: BCLI READ ACF EQUITY RESEARCH'S...

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn PR Newswire The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, see...